---

---

“Among the many strengths of the book is its ability to provide a message of hope despite acknowledging the impact of methamphetamine addiction and the obstacles to its successful treatment. Eschewing the sensationalism often found in media coverage of methamphetamine, Methamphetamine Addiction relies instead on evidence-based scholarship that is frequently discussed in the context of other drug 'epidemics'....A comprehensive, authoritative review of methamphetamine's effects from synapse to society. It is an outstanding reference for psychiatrists, psychologists, social workers, and other addiction treatment providers who encounter methamphetamine dependence in clinical practice. Above all, the book provides a message of hope to all patients, their families, clinicians, and policy makers that treatment is not futile and recovery is possible.”

—Journal of Psychiatric Practice


“Contribute[s] excellent reviews of the methamphetamine problem by experts in the abuse field.”

—PsycCRITIQUES


“Dr. John M. Roll and coeditors have captured the essence of methamphetamine, from its basic neuropharmacologic mechanisms to the nightmarish consequences of this drug for community systems. The comprehensive expertise the editors and contributors bring to this volume is impressive, spanning the fields of psychology; neurology; psychiatry; family, internal, and behavioral medicine; epidemiology; functional neuroimaging; multiple basic science disciplines; and the advocacy and legal realms. Skillfully compiled and eminently readable, this volume has utility not just for addiction clinicians, teachers, and researchers, but also for those in a variety of other academic disciplines. Content relevant to sociology, anthropology, and human behavior in general is digestible enough in this book for use at an undergraduate curriculum level, yet in-depth and literature-based enough to support post-graduate work. Psychiatry residency, addictions medicine, and psychiatry fellowship programs may all want to take a look at this book for use in graduate medical education....Well-organized and thorough....If you are interested in understanding the methamphetamine 'big picture,' this book is for you.”

—Journal of Clinical Psychiatry


“The medical consequences of methamphetamine use are covered in a comprehensive and accessible way, addressing all major systems affected in addition to implications of the disinhibiting effect of the drug leading to accidents and high-risk sexual activity. Psychiatric presentations are also adequately covered, including psychotic symptoms and comorbidity. The neuro-cognitive deficits demonstrated in longer-term users of methamphetamine and their impact on treatment success is a common theme throughout the book.”

—British Journal of Psychiatry


“This definitive, timely book broadens the understanding of methamphetamine addiction and its treatment with in-depth coverage of such diverse topics as epidemiology, neuropharmacology, psychiatric consequences, psychosocial interventions, and pharmacological interventions. Grounded in research data and clinical experience, the book will be of immense value to practitioners, researchers, and students.”

—Arnold M. Washton, PhD, Executive Director, Recovery Options, New York, New York, and Princeton, New Jersey


“The field has clearly been lacking a comprehensive reference like this one. Contributors include foremost experts, who offer up-to-date, authoritative presentations. This information should be widely disseminated among treatment professionals as we confront this grave addiction that affects so many Americans.”

—Thomas R. Kosten, MD, Jay H. Waggoner Chair and Professor of Psychiatry and Neuroscience, Baylor College of Medicine


“This skillfully crafted volume belongs in the library of every addictions professional. Among the book's unique contributions is the way it addresses methamphetamine at multiple levels of analysis, from cellular effects and community impacts to best practices in treatment and prevention. It also goes a long way in correcting popular misconceptions. Given its coherence and breadth, this book is well suited to be a supplemental text in graduate-level courses on addictions. Students will benefit greatly from the integrated coverage of biological, psychological, social, and environmental factors in methamphetamine addiction and its treatment.”

—Meredith Hanson, DSW, Professor and Director, Doctoral Program in Social Work, Fordham University Graduate School of Social Service

---

Table of Contents

1.Introduction, John M. Roll, Richard A. Rawson, Steven Shoptaw, and Walter Ling

2. Epidemiology of Methamphetamine Use: A Global Perspective, Beth A. Rutkowski and Jane C. Maxwell

3. Basic Neuropharmacological Mechanisms of Methamphetamine, Glen R. Hanson and Annette E. Fleckenstein

4. Methamphetamine and the Brain: Findings from Brain Imaging Studies, Doris Payer and Edythe D. London

5. Behavioral Pharmacology and Psychiatric Consequences of Methamphetamine, Craig R. Rush, William W. Stoops, and Walter Ling

6. Medical Effects of Methamphetamine Use, Larissa Mooney, Suzette Glasner-Edwards, Richard A. Rawson, and Walter Ling

7. Public Health Issues Surrounding Methamphetamine Dependence, Steven Shoptaw, William D. King, Evan Landstrom, Michelle A. Bholat, Keith Heinzerling, Gregory D. Victorianne, and John M. Roll

8. Methamphetamine and Crime, David Farabee and Angela Hawken

9. Effects of Methamphetamine on Communities, Linda J. Thompson, Sharon Sowell, and John M. Roll

10. Psychosocial and Behavioral Treatment of Methamphetamine Dependence, Steven Shoptaw, Richard A. Rawson, Matthew Worley, Sarah Lefkowith, and John M. Roll

11. Pharmacological Treatment of Methamphetamine Addiction, Frank J. Vocci, Ahmed Elkashef, and Nathan M. Appel

12. Treatment of Methamphetamine Addiction That Co-occurs with Serious Mental Illness, Jagoda Pasic and Richard Ries

13. Conclusion, Charles R. Schuster, Chris-Ellyn Johanson, and John M. Roll

---

About the Editors

John M. Roll, PhD, is Professor and Associate Dean for Research at Washington State University College of Nursing in Spokane and Director of its Program of Excellence in the Addictions. He is a Fellow of the American Psychological Association, President of the association's Division on Psychopharmacology and Substance Abuse, and was a vice-chairman of the Washington State Governor’s Council on Substance Abuse. Dr. Roll has received research funding from federal, state, and local sources, as well as foundation and industry support.

Richard A. Rawson, PhD, is Associate Director of the UCLA Integrated Substance Abuse Programs, one of the foremost substance abuse research groups, and Professor-in-Residence in the Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Rawson oversees clinical trials on pharmacological and psychosocial addiction treatments. He served on the Federal Methamphetamine Advisory Group from 1996 to 1999.

Walter Ling, MD, is a board-certified neurologist and psychiatrist, Professor- in-Residence of Psychiatry at the David Geffen School of Medicine at the University of California, Los Angeles, and Director of the UCLA Integrated Substance Abuse Programs. He is a consultant for numerous local, national, and international private and public agencies. Dr. Ling's current research program is designed to bring cutting-edge findings from treatment research to practice in community treatment programs.

Steven Shoptaw, PhD, is Professor of Family Medicine and of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Shoptaw’s research involves developing and implementing efficacious treatments for individuals with various drug dependence problems, particularly for those with stimulant dependence and risks for HIV infection and other health care problems.

---

Contributors

Nathan M. Appel, PhD, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, Maryland

Michelle A. Bholat, MD, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Ahmed Elkashef, PhD, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, Maryland

David Farabee, PhD, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Annette E. Fleckenstein, PhD, Department of Pharmacology and Toxicology, College of Pharmacy, Salt Lake City, Utah

Suzette Glasner-Edwards, PhD, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Glen R. Hanson, DDS, Department of Pharmacology and Toxicology, College of Pharmacy, Salt Lake City, Utah

Angela Hawken, PhD, UCLA Integrated Substance Abuse Programs and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Keith Heinzerling, MD, MPH, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Chris-Ellyn Johanson, PhD, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Chicago, Illinois

William D. King, MD, JD, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Evan Landstrom, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Sarah Lefkowith, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Walter Ling, MD, UCLA Integrated Substance Abuse Programs, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California Edythe D. London, PhD, Neuropsychiatric Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Jane C. Maxwell, PhD, Addiction Research Institute, University of Texas at Austin, Austin, Texas

Larissa Mooney, MD, UCLA Integrated Substance Abuse Programs and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Jagoda Pasic, MD, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington at Harborview Medical Center, Seattle, Washington

Doris Payer, BS, Neuropsychiatric Institute, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Richard A. Rawson, PhD, UCLA Integrated Substance Abuse Programs, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Richard Ries, MD, Department of Psychiatry and Behavioral Sciences, University of Washington at Harborview Medical Center, Seattle, Washington

John M. Roll, PhD, Intercollegiate College of Nursing, Washington State University, Spokane, Washington

Craig R. Rush, PhD, College of Medicine, University of Kentucky, Lexington, Kentucky

Beth A. Rutkowski, MPH, UCLA Integrated Substance Abuse Programs, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Charles R. Schuster, PhD, Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Chicago, Illinois

Steven Shoptaw, PhD, Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, California

Sharon Sowell, BA, Department of Clinical Psychology, Washington State University, Spokane, Washington

William W. Stoops, PhD, Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, Kentucky

Linda J. Thompson, MA, Greater Spokane Substance Abuse Council, Spokane Valley, Washington

Gregory D. Victorianne, BA, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

Frank J. Vocci, PhD, Friends Research Institute, Baltimore, Maryland

Matthew Worley, BA, Department of Family Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California

---

Audience

Clinical psychologists, psychiatrists, social workers, substance abuse counselors, psychiatric nurses, and other professionals who treat addictions and substance abuse; graduate students in these areas.

---

Course Use

May serve as a supplemental text in graduate-level courses.